← Home
Eli Lilly and Company 
Pharma / Pharma
Press Releases
| Date | Press release |
|---|---|
| 2025-05-01 06:45:00 | Lilly Reports First-quarter 2025 Financial Results And Highlights Pipeline Momentum Revenue in q1 2025 increased 45% to $12.73 billion driven by volume growth from mounjaro and zepbound. pipeline progress included positive phase 3 trial results for orforglipron (small molecule oral glp-1 agonist) in type 2 diabetes in the first of seven obesity and diabetes phase 3 trials. |
| 2025-04-29 10:07:00 | Creyon Bio And Lilly Enter Into Rna-targeted Oligo Therapy Development Collaboration San diego--(business wire)-- #aiinhealthcare--creyon bio, inc. (“creyon”) today announced a global licensing and multi-target research collaboration with eli lilly and company (“lilly”) focused on the discovery, development and commercialization of novel rna-targeted oligonucleotide (oligo) therapies for a broad range of diseases. as a part of the collaboration, creyon will leverage its industry-first ai-powered oligo engineering engine to design and optimize new drug candidates for lilly’s named targets on time. |
| 2025-04-17 10:00:00 | Lilly Confirms Date And Conference Call For First-quarter 2025 Financial Results Announcement Indianapolis , april 17, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) will announce its first-quarter 2025 financial results on may 1, 2025. lilly will also conduct a conference call that day with the investment community and media to further detail the company’s financial performance. |
| 2025-04-17 09:00:00 | Bighat Biosciences And Lilly Collaborate To Advance Ai-driven Antibody Therapeutics San mateo, calif.--(business wire)--bighat biosciences (“bighat”), a biotechnology company with a machine learning (ml)-guided antibody discovery and development platform, announced a strategic collaboration with eli lilly and company (“lilly”). in this collaboration, bighat will deploy its milliner platform, a suite of state-of-the-art ml technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies with superior functionality. bighat. |
| 2025-04-17 06:45:00 | Lilly’s Oral Glp-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results And A Safety Profile Consistent With Injectable Glp-1 Medicines In Successful Phase 3 Trial Orforglipron is the first small molecule glp-1 to successfully complete a phase 3 trial, lowering a1c by an average of 1.3% to 1.6% across doses the investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint the overall safety and tolerability profile of orforglipron in achieve-1 was consistent with injectable glp-1 therapies indianapolis , april 17, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) today announced positive topline phase 3 results from achieve-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. orforglipron is the first oral small molecule glucagon-like peptide-1 (glp-1) receptor agonist, taken without food and water restrictions, to successfully complete a phase 3 trial. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal